Bonk (NASDAQ:BNKK) Releases Earnings Results

Bonk (NASDAQ:BNKK) issued its earnings results on Friday. The company reported ($0.76) EPS for the quarter, FiscalAI reports. Bonk had a negative net margin of 838.37% and a negative return on equity of 148.62%. The firm had revenue of $1.16 million during the quarter.

Bonk Trading Up 5.9%

BNKK traded up $0.06 during trading on Friday, hitting $1.08. The company’s stock had a trading volume of 76,888 shares, compared to its average volume of 703,868. The firm has a market capitalization of $8.68 million, a price-to-earnings ratio of -0.23 and a beta of 1.98. The business’s fifty day simple moving average is $1.28 and its 200 day simple moving average is $2.34. Bonk has a twelve month low of $0.91 and a twelve month high of $25.04.

Hedge Funds Weigh In On Bonk

A number of large investors have recently added to or reduced their stakes in BNKK. Geode Capital Management LLC acquired a new stake in shares of Bonk in the fourth quarter valued at about $128,000. Jane Street Group LLC acquired a new stake in shares of Bonk in the fourth quarter worth approximately $96,000. BlackRock Inc. acquired a new position in Bonk in the 2nd quarter valued at $50,000. Steward Partners Investment Advisory LLC acquired a new stake in Bonk during the 4th quarter worth $37,000. Finally, State Street Corp purchased a new stake in shares of Bonk during the fourth quarter worth $33,000. 12.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on BNKK shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Bonk in a report on Friday, July 24th. Wall Street Zen upgraded Bonk from a “sell” rating to a “hold” rating in a research report on Saturday, July 4th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Bonk Company Profile

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.